Moreover, most of the molecules, such as inhibitors or compounds (synthetic or natural agents) used to reactivate and restore p53 function in CRC cells, were only tested in vitro and in animal models but not yet in clinical trials [107]. The gene discussed is TP53; the disease is colorectal carcinoma.